HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

Senior Editor

New York, NY
Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest From Jessica Merrill

Agios Extends Cash Runway With $905m Royalty Pharma Deal

Deal Snapshot: Agios sold rights to a 15% royalty on US net sales of the IDH1/2 inhibitor vorasidenib, which it sold to Servier in 2020.

Deals Cancer

Development Versus Dealmaking: How To Obtain A Blockbuster

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

Business Strategies Companies

Takeda Goes In On Molecular Glue Degraders With Degron Deal

The company will pay $1.2bn in upfront and milestone fees to access Degron’s GlueXplorer platform across multiple therapeutic areas.

Deals Innovation

More Cost Cuts At Pfizer Bring Total Savings To $5.5bn

A new round of cost-cutting at Pfizer will deliver savings of $1.5bn by the end of 2027, the company reported in an SEC filing.

Companies Business Strategies

Rezolute Sees Big Opportunity For Oral Eye Disease Drug

The company reported positive topline data from a Phase II study testing RZ402 in patients with diabetic macular edema.

Clinical Trials Ophthalmic

Lilly Inks Follow-Up Radiopharmaceuticals Deal With Aktis

The big pharma will pay $60m upfront and make an equity investment in the Boston-based startup.

Deals Cancer
See All
UsernamePublicRestriction

Register